Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 3/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.59 |
| ▸ | BAD | Q92934 | 1/20 | 0.59 |
| ▸ | FNTA | P49354 | 2/20 | 0.54 |
| ▸ | FNTB | P49356 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.44 |
| ▸ | GCGR | P47871 | 2/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6928721 | 0.83 | MEN1 (0.51) | BCL2MCL1BADFNTAFNTB | |
| SCHEMBL15313717 | 0.81 | MCL1 (0.76) | BCL2MCL1BADFNTAFNTB | |
| SCHEMBL6599085 | 0.77 | MEN1 (0.56) | MCL1SMN1; SMN2ALDH1A1MEN1MAPT | |
| SCHEMBL15313720 | 0.74 | BCL2 (1.00) | BCL2MCL1BADFNTAFNTB | |
| SCHEMBL8398501 | 0.73 | NR4A1 (0.53) | BCL2MCL1BADFNTAFNTB | |
| SCHEMBL10537061 | 0.72 | SRD5A2 (0.71) | BCL2MCL1BADSRD5A2PARP10 | |
| SCHEMBL6923020 | 0.71 | MAPT (0.50) | SMN1; SMN2ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL976142 | 0.71 | HDAC8 (0.60) | MCL1SMN1; SMN2MEN1MAPTKMT2A | |
| SCHEMBL31254507 | 0.70 | SRD5A2 (0.59) | BCL2MCL1BADSMN1; SMN2ALDH1A1 | |
| SCHEMBL27527408 | 0.70 | FNTA (0.52) | BCL2MCL1BADFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1045846-B1 | IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF | LG CHEMICAL LTD (KR) | 2003-05-02 | — | — | EP | disclosed |
| US-6518429-B2 | Anticancer agents, treating restenosis, atherosclerosis and hepatitis virus | LG CHEMICAL, LTD. (KR) | 2003-02-11 | — | — | US | disclosed |
| US-6472526-B1 | SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ISOMERS THEREOF, IN PHARMACEUTICAL COMPOSITION AND INTERMEDIATES | LG CHEMICAL LTD. (KR) | 2002-10-29 | — | — | US | disclosed |
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | LG CHEMICAL LTD. | 2002-09-26 | — | — | US | disclosed |
| US-6268363-B1 | ANTITUMOR | LG CHEMICAL LTD. (KR) | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137769-A1 | Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof | FNTA, FNTB, FDPS | BCL2 4618/4885MCL1 1991/4885BAD 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.